Overexpression of osteopontin in clear cell carcinoma of the ovary: Close association with HNF-1β expression

Histopathology

Volumn 52, Issue 6, 2008, Pages 682-688

  Kato, N ^a   Motoyama, T ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Clear cell carcinoma; HNF 1 ; Osteopontin; Ovary

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 1BETA; MESSENGER RNA; OSTEOPONTIN;

ARTICLE; CANCER CELL CULTURE; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA, CLEAR CELL; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HUMANS; OSTEOPONTIN; OVARIAN NEOPLASMS; OVARY; UP-REGULATION;

EID: 42649088733     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03006.x     Document Type: Article

References (39)

1. Schwartz DR, Kardia SL, Shedden KA et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002 62 4722 4729.
2. Tsuchiya A, Sakamoto M, Yasuda J et al. Expression profiling in ovarian clear cell carcinoma. Identification of hepatocyte nuclear factor-1beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am. J. Pathol. 2003 163 2503 2512.
3. Lu KH, Patterson AP, Wang L et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 2004 10 3291 3300.
4. Kato N, Sasou S, Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod. Pathol. 2006 19 83 89.
5. Higashiguchi A, Yamada T, Susumu N et al. Specific expression of hepatocyte nuclear factor-1beta in the ovarian clear cell adenocarcinoma and its application to cytological diagnosis. Cancer Sci. 2007 98 387 391.
6. Kato N, Toukairin M, Asanuma I, Motoyama T. Immunocytochemistry for hepatocyte nuclear factor-1beta (HNF-1beta): a marker for ovarian clear cell carcinoma. Diagn. Cytopathol. 2007 35 193 197.
7. Courtois G, Baumhueter S, Crabtree GR. Purified hepatocyte nuclear factor 1 interacts with a family of hepatocyte-specific promoters. Proc. Natl Acad. Sci. U.S.A. 1988 85 7937 7941.
8. Senkel S, Lucas B, Klein-Hitpass L, Ryffel GU. Identification of target genes of the transcription factor HNF-1beta and HNF-1alfa in a human embryonic kidney cell line. Biochim. Biophys. Acta 2005 20 179 190.
9. Benedet JL, Bender H, Jones HW III. et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO committee on Gynecologic Oncology. Int. J. Gynaecol. Obstet. 2000 70 209 262.
10. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int. J. Gynecol. Pathol. 2000 19 7 15.
11. Haumaitre C, Fabre M, Cormier S, Baumann C, Delezoide AL, Cereghini S. Severe pancreas hypoplasia and multicystic renal dysplasia in two human fetuses carrying novel HNF1beta/MODY5 mutations. Hum. Mol. Genet. 2006 15 2363 2375.
12. Yamamoto S, Tsuda H, Aida S, Shimazaki H, Tamai S, Matsubara O. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear cell adenocarcinoma and nonneoplastic endometrium. Hum. Pathol. 2007 38 1074 1080.
13. Wang W, Hayashi Y, Ninomiya T et al. Expression of HNF-1 alpha and HNF-1 beta in various histological differentiations of hepatocellular carcinoma. J. Pathol. 1998 184 272 278.
14. Furger KA, Menon RK, Tuck AB, Bramwell VHC, Chambers AF. The functional and clinical roles of osteopontin in cancer and metastasis. Curr. Mol. Med. 2001 1 621 632.
15. Rittling SR, Chambers AF. Role of osteopontin in tumor progression. Br. J. Cancer 2004 90 1877 1881.
16. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, MaCann M, Rudland PS. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev. 2006 17 463 474.
17. Kim JH, Skates SJ, Uede T et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002 287 1671 1679.
18. Patarca R, Freeman GJ, Singh RP et al. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J. Exp. Med. 1989 170 145 161.
19. Brown LF, Papadopoulos-Sergiou A, Berse B et al. Osteopontin expression and distribution in human carcinomas. Am. J. Pathol. 1994 145 610 623.
20. Tiniakos DG, Yu H, Liapis H. Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP). Hum. Pathol. 1998 29 1250 1254.
21. Maki M, Hirota S, Kaneko Y, Morohoshi T. Expression of osteopontin messenger RNA by macrophages in ovarian serous papillary cystadenocarcinoma: a possible association with calcification of psammoma bodies. Pathol. Int. 2000 50 531 535.
22. Coppola D, Szabo M, Boulware D et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin. Cancer Res. 2004 10 184 190.
23. O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG. An immunohistochemical comparison between low-grade and high grade ovarian serous carcinomas. Significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am. J. Surg. Pathol. 2005 29 1034 1041.
24. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006 16 79 87.
25. Liapis H, Adler LM, Wick MR, Rader JS. Expression of v β 3αvβ3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum. Pathol. 1997 28 443 449.
26. Rodriguez-Rodriguez L, Sancho-Torres I, Leakey P et al. CD44 splice variant expression in clear cell carcinoma of the ovary. Gynecol. Oncol. 1998 71 223 229.
27. Wang D, Yamamoto S, Hijiya N, Benveniste EN, Gladson CL. Transcriptional regulation of the human osteopontin promoter: functional analysis and DNA-protein interactions. Oncogene 2000 19 5801 5809.
28. Liu YN, Kang BB, Chen JH. Transcriptional regulation of the human osteopontin promoter by C-EBP alpha and AML-1 in metastatic cancer cells. Oncogene 2004 23 278 288.
29. Senger DR, Wirth DF, Hynes RD. Transformation-specific secreted phosphoproteins. Nature 1980 286 619 621.
30. Caers J, Gunthert U, De Raeve H et al. The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model. Br. J. Haematol. 2006 132 469 477.
31. Hsieh YH, Juliana MM, Hicks PH et al. Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin. Cancer Res. 2006 66 7119 7127.
32. Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW, Chen JY. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44v interaction enhances survival in gastrointestinal cancer cells. Cancer Res. 2007 67 2089 2097.
33. Graessmann M, Berg B, Fuchs B, Klein A, Graessmann A. Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3. Oncogene 2006 26 2840 2850.
34. Goff BA, Sainz de la Cuesta R, Muntz HG et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol. Oncol. 1996 60 412 417.
35. Tammela J, Geisler JP, Eskew JrPN, Geisler HE. Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma. Eur. J. Gynaecol. Oncol. 1998 19 438 440.
36. Sugiyama T, Kamura T, Kigawa J et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000 88 2584 2589.
37. Miyashita T, Reed CJ. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993 81 151 157.
38. Weller M, Malipiero U, Aguzzi A et al. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Invest. 1995 95 2633 2643.
39. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004 23 2934 2949.